Novo Nordisk trial with next-gen diabetes drug shows 15.7% weight loss but shares fall
Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 ...
STAT3d
Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial
Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...
Devdiscourse4d
Novo Nordisk's CagriSema: A Breakthrough in Weight Loss for Type 2 Diabetes
Novo Nordisk's new drug, CagriSema, showed promising results in reducing weight among overweight or obese type 2 diabetes patients. During the phase III REDEFINE 2 trial, participants experienced a 15 ...
Medical Dialogues4d
Hetero Labs Gets CDSCO Panel Nod To study Semaglutide Injection for Type 2 Diabetes Mellitus
This came after Hetero Labs presented the BE study protocol, vide no. AZBE112405, Version No. 01, Dated 15.11.2024 and the ...
Medical Dialogues5d
Alkem Laboratories Gets CDSCO Panel Nod To study Semaglutide tablet for Type 2 Diabetes Mellitus
This came after Alkem Laboratories presented BE study protocol vide no. BIOS/2024/128, Version No. 01, Dated 17.07.2024 and ...
Devdiscourse4d
Novo Nordisk's CagriSema: A Weight-Loss Hopeful Under Market Scrutiny
Novo Nordisk's trial results for CagriSema, a next-gen obesity and diabetes drug, showed a 15.7% weight reduction in overweight patients with type 2 diabetes. Despite promising outcomes, shares ...
Novo Nordisk says trial with next-gen drug in diabetics shows 15.7% weight loss
Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 ...